Seres Therapeutics (MCRB) Financials: History & Chart

Seres Therapeutics, Inc.(MCRB)

Biotechnology · Cambridge, MA

$2.850.00 (0.00%)

Delayed quote: Oct 6, 2026, 3:18 PM EDT

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Cambridge, MA

66 employees

www.serestherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard N. Kender

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.88M	736K	358K	438K	351K	0.00	0.00	0.00	0.00
Cost of Goods Sold	328K	0.00	781K	-13.80M	13.35M	1.06M	3.53M	5.13M	1.40M
Gross Profit	1.55M	736K	-423K	14.24M	-13.00M	-1.06M	-3.53M	-5.13M	-1.40M
Gross Profit Margin	82.6%	100.0%	-118.2%	3251.8%	-3704.0%	N/A	N/A	N/A	N/A
Total Operating Expenses	85.59M	22.01M	20.48M	33.62M	9.48M	23.82M	23.71M	23.71M	27.77M
Research & Development	46.64M	9.14M	13.20M	11.68M	12.62M	12.94M	11.82M	12.84M	16.46M
Selling, General & Administrative	32.15M	7.06M	8.07M	7.54M	9.48M	10.25M	11.89M	12.46M	11.31M
Operating Income (EBIT)	-84.03M	-21.27M	-20.91M	-19.38M	-22.48M	-24.88M	-27.24M	-28.84M	-29.17M
Operating Margin	-4462.8%	-2890.4%	-5839.9%	-4424.0%	-6403.7%	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-22.46M	4.58M	-19.91M	-15.34M	8.20M	-19.86M	32.68M	-15.64M	-51.03M
Interest Income	1.57M	181K	325K	445K	618K	546K	618K	437K	652K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	61.57M	25.85M	994K	4.04M	30.68M	5.03M	59.92M	13.20M	-21.86M
Net Income	-22.46M	4.58M	-19.91M	-15.34M	8.20M	-19.86M	32.68M	-15.64M	88.78M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-1192.9%	622.4%	-5562.3%	-3501.1%	2337.3%	N/A	N/A	N/A	N/A
EBITDA	-79.39M	-20.60M	-20.13M	-17.24M	-21.42M	-23.82M	-26.16M	-27.75M	-27.77M
EBITDA Margin	-4216.1%	-2799.3%	-5621.8%	-3936.5%	-6102.0%	N/A	N/A	N/A	N/A
Depreciation & Amortization	4.64M	670K	781K	2.13M	1.06M	1.06M	1.08M	1.08M	1.40M
EPS Basic	-2.42	0.49	-2.08	-1.77	0.94	-2.27	3.76	-1.81	N/A
EPS Diluted	-2.41	0.49	-2.08	-1.76	0.94	-2.27	3.75	-1.81	N/A
Weighted Average Basic Shares	9.64M	9.64M	9.58M	8.86M	8.76M	8.74M	8.70M	8.65M	7.63M
Weighted Average Diluted Shares	9.64M	9.64M	9.58M	8.87M	8.77M	8.74M	8.71M	8.65M	7.63M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	789K	0.00	0.00	0.00	144.93M	33.22M	34.51M	28.27M
Cost of Goods Sold	4.13M	3.53M	19.34M	0.00	0.00	90.57M	0.00	95.95M
Gross Profit	-3.34M	-3.53M	-19.34M	0.00	144.93M	-57.35M	34.51M	-67.69M
Gross Profit Margin	-423.8%	N/A	N/A	N/A	100.0%	-172.7%	100.0%	-239.5%
Total Operating Expenses	90.63M	117.78M	175.76M	179.91M	209.42M	30.77M	106.38M	128.55M
Research & Development	49.06M	64.60M	117.60M	109.65M	141.89M	90.57M	80.14M	95.95M
Selling, General & Administrative	39.16M	53.18M	77.50M	70.26M	69.26M	30.77M	24.75M	32.60M
Operating Income (EBIT)	-93.97M	-121.31M	-195.10M	-179.91M	-64.49M	-88.13M	-71.88M	-100.28M
Operating Margin	-11910.1%	N/A	N/A	N/A	-44.5%	-265.3%	-208.3%	-354.8%
Income Before Tax (EBT)	5.70M	-125.77M	-190.13M	-183.58M	-65.58M	-89.13M	-70.28M	-98.94M
Interest Income	2.23M	3.97M	7.30M	3.06M	2.87M	946K	1.03M	N/A
Interest Expense	N/A	N/A	13.18M	6.02M	2.91M	2.92M	502K	1.17M
Other Income/Expense	99.67M	-4.46M	4.97M	-3.67M	-1.08M	-997K	1.60M	1.34M
Net Income	5.70M	-146.57M	-113.72M	-250.16M	-65.58M	-89.13M	-70.28M	-98.94M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	721.9%	N/A	N/A	N/A	-45.2%	-268.3%	-203.7%	-350.0%
EBITDA	-89.84M	-115.85M	-188.85M	-173.28M	-58.55M	-79.24M	-64.27M	-92.42M
EBITDA Margin	-11386.3%	N/A	N/A	N/A	-40.4%	-238.6%	-186.3%	-327.0%
Depreciation & Amortization	4.13M	5.47M	6.24M	6.63M	5.95M	8.89M	7.60M	7.86M
EPS Basic	0.64	-18.86	-17.77	-46.29	-14.30	-22.34	-24.81	-48.57
EPS Diluted	0.64	-18.86	-17.77	-46.29	-14.30	-22.34	-24.81	-48.57
Weighted Average Basic Shares	8.86M	7.77M	6.40M	5.40M	4.59M	3.99M	2.83M	2.04M
Weighted Average Diluted Shares	8.87M	7.77M	6.40M	5.40M	4.59M	3.99M	2.83M	2.04M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.